The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Verisurf Software, OptiPro Systems Announce Metrology Reseller Agreement
Verisurf Software, Inc. and OptiPro Systems, LLC, announced the signing of a reseller agreement.
Meet the NDT Expert of Las Vegas
After Greg Weaver got out of the Navy, he started working in mining in northern Nevada. After a…
Why Manufacturing Data Collection Matters More Than Ever
Manufacturing decisions are only as good as the data behind them.